$2 / month

Comment and reply across TML.

Start or manage membership

Most pulsed

Advertisement Sinscents Bad Intentions. Great Candles.

Latest from other desks

tml.the modern leap
Health / Medical Research

FDA Approves Klygefa, a Weekly Self-Injection for Myasthenia Gravis

The FDA has approved Klygefa (gefurulimab) for adults with generalized myasthenia gravis who test positive for anti-acetylcholine receptor antibodies, AstraZeneca's rare disease arm Alexion announced on Monday, November 16. It's the first dual-binding nanobody C5 inhibitor cleared in the United States, and patients give it to themselves once a week with an autoinjector.

The drooping eyelid, or ptosis, of a patient with myasthenia gravis, one of the disease's first and most common signs (archive). Photo: Cumulus, CC BY-SA 3.0, via Wikimedia Commons.
Summary

The drug class isn't new. The delivery is. A C5 inhibitor a patient injects at home once a week replaces a treatment routine built around infusion appointments, and that's the ground Klygefa is taking.

Tap a passage. React to the part that matters.

The Food and Drug Administration has approved Klygefa (gefurulimab) for adults with generalized myasthenia gravis who are anti-acetylcholine receptor (AChR) antibody positive, Alexion, AstraZeneca's rare disease unit, announced on Monday, November 16. The approval rests on the phase III PREVAIL trial, which enrolled 260 patients across 20 countries. At week 26, patients on Klygefa improved on the Myasthenia Gravis Activities of Daily Living scale by 1.6 points more than patients on placebo (treatment difference -1.6; 95% CI -2.4 to -0.8; p<0.0001), and the company says improvement showed as early as week one.

Myasthenia gravis is a rare autoimmune disorder in which the immune system attacks the neuromuscular junction, the connection point where nerves tell muscles to move. About 85 percent of patients carry the anti-AChR antibodies the drug is approved for. AstraZeneca estimates 98,500 people in the United States are diagnosed with the generalized form, 81,000 of them AChR-positive. The first signs are often small ones, slurred speech, double vision, a drooping eyelid. As the disease progresses they can become impaired swallowing, choking, extreme fatigue and respiratory failure.

Klygefa's mechanism is complement blockade with a delivery twist. It's a nanobody that binds the C5 protein in the terminal complement cascade, stopping the immune attack on the junction, and it binds serum albumin at the same time, which stretches its half-life far enough to allow once-weekly dosing. Patients take a single weight-based loading dose on day one, then a weight-based maintenance dose from day eight, once a week, injected under the skin by autoinjector at home. Alexion calls it the first and only dual-binding nanobody C5 inhibitor approved in the United States.

PREVAIL randomized patients 1:1 to Klygefa or placebo for 26 weeks. Participants had a confirmed diagnosis for at least three months, a positive AChR antibody test, and disease rated class II to IV on the Myasthenia Gravis Foundation of America scale. The trial's results were presented at the MGFA Scientific Session at the AANEM 2025 annual meeting and published in JAMA Neurology. Patients who finished the controlled period could roll into an open-label extension that's still running, and the company says the functional gains held through one year of treatment.

On safety, the share of patients reporting treatment-emergent adverse events was similar on Klygefa and placebo, and most events were mild to moderate. The most common on the drug were injection site reactions at 12 percent, back pain at 8 percent and vomiting at 5 percent. Alexion says the profile is consistent with the two older C5 inhibitors used in this disease, eculizumab and ravulizumab, both of which are given intravenously on a clinic schedule.

"gMG is a disease marked by unpredictability and variability, for which early intervention and reliable disease control are critical treatment goals," said Kelly Gwathmey, MD, of Columbia University's Vagelos College of Physicians and Surgeons, a principal investigator in the trial at Virginia Commonwealth University. Samantha Masterson, president and CEO of the Myasthenia Gravis Foundation of America, put the patient side of it plainly: every new approved treatment "represents choice," because no two patients experience the disease the same way. Klygefa is already approved in the European Union, Japan and other countries for certain adults with the disease, and filings based on PREVAIL are under review in China and elsewhere.

Sources

The conversation

A little more perspective.

Reading is free. Verified members can comment and reply for $2 a month.

The conversation.

Loading comments…

Keep your curiosity going.

Some links here are affiliate links. If you buy through one, we might make a commission — it never changes what you pay. As an Amazon Associate I earn from qualifying purchases.